And last month, the company completed a rights offering with the investment banking arm of Maxim Group. We closed on a $2.5 million bridge loan from the company's Vice Chair of the Board of Directors, Mr. During the second quarter of 2022 and since, we continue to work on financing for the company. Investors should read carefully the risks and uncertainties described within the safe harbor section of our website as well as the risk factors included in the company's most recent quarterly and annual filings with the SEC.
ONCE UPON A TIME PILOT TRANSCRIPT UPDATE
We assume no obligation to revise or update forward-looking statements, whether as a result of new information, future events or otherwise. These statements involve certain assumptions, risks and uncertainties and could cause actual results to differ materially. All of these statements are based on the beliefs and expectations of management as of today. These events relate to our business plans to develop Navidea's molecular diagnostics and immunotherapeutics, which include clinical and regulatory developments and timing of clinical data readouts, along with capital resources and strategic matters as well as the impact of the COVID-19 pandemic on Navidea's business operations. During the course of this conference call, we will be making forward-looking statements regarding future events and the future performance of the company. Kim Scott and its Vice President of Finance and Administration, Erika Eves, are joining me on the call today. Navidea's Chair of its Board of Directors, Mr. Following prepared remarks, we will be conducting a live question-and-answer session. There is an accompanying slide deck that is also being displayed. This call is being webcast live on our website, ir., and a replay will be made available. Senior VP & Chief Medical Officer - Thank you, and thank you all for joining us here today. Michael Stanley Rosol, Navidea Biopharmaceuticals, Inc. I will now turn the conference over to Dr. (Operator Instructions) And please note that this conference is being recorded.
Welcome to the Navidea QuarEarnings Call and Business Update. Senior VP & Chief Medical Officer = Conference Call Participants = * Fredric Zaino Keystone Capital Partners LLC - Managing Partner & CIO * Michael Okunewitch Maxim Group LLC, Research Division - Senior Research Analyst = Presentation - Operator - Greetings. Vice Chairman * Michael Stanley Rosol Navidea Biopharmaceuticals, Inc. VP of Finance & Administration * John K. Cappello Navidea Biopharmaceuticals, Inc.
ONCE UPON A TIME PILOT TRANSCRIPT FREE
We welcome any questions, and are here for any issues.Thank you for stopping in Pictures sell!Auctiva offers Free Image Hosting and Editing.250+ Listing Templates!Auctiva gets you noticed!The complete eBay Selling Solution.Q2 2022 Navidea Biopharmaceuticals Inc Earnings Call and Business Update DUBLIN (Thomson StreetEvents) - Edited Transcript of Navidea Biopharmaceuticals Inc earnings conference call or presentation Thursday, Septemat 8:00:00pm GMT TEXT version of Transcript = Corporate Participants = * Alexander L. SCRIPTS SHIP IN STURDY PACKAGING TO GUARANTEE SAFE ARRIVAL. ONCE UPON A TIME PILOT SCRIPT SIGNED RPT JENNIFER MORRISON, JOSH DALLAS + MORE a.imagelink PLEASE READ THIS DESCRIPTION THOROUGHLY OWN THIS TIMELESS PIECE OF HOLLYWOOD MEMORABILIA YOU ARE CONSIDERING A COLOR REPRODUCTION OF THE COMPLETE SCRIPT FOR ONCE UPON A TIME "PILOT" COMPLETE EPISODE WRITTEN BY EDWARD KITSIS & ADAM HOROWITZ THE FINEST LAZER REPRODUCTION OF CAST SIGNATURES JENNIFER MORRISON, JOSH DALLAS LAN PARRILLA, JAMIE DORNAN RAPHAEL SBARGE, GINNIFER GOODWIN ROBERT CARLYLE, JARED GILMORE LEE ARENBERG, TONY AMENDOLA KEEGAN CONNOR TRACY, MEGHAN ORY BEVERLY ELLIOTT ALL SCRIPTS INDUSTRY STANDARD, 8 1/2" X 11" PAPER 3 HOLE PUNCH LEFT SIDE, BRASS BRAD CONNECTIONS. Item: 264433385791 ONCE UPON A TIME PILOT SCRIPT SIGNED RPT JENNIFER MORRISON, JOSH DALLAS + MORE.
0 kommentar(er)
